| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3523 |
| Trial ID | NCT05963217 |
| Disease | B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | TBI-2001 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) |
| Year | 2023 |
| Country | Canada |
| Company sponsor | University Health Network, Toronto |
| Other ID(s) | TBI-200101 |
| Cohort 1 | |||||||||||||
|
|||||||||||||